---
schema_version: "secwatch.filing_event.v1"
accession: "0001739410-24-000053"
form_type: "8-K"
ticker: "RLYB"
cik: "0001739410"
company_name: "Rallybio Corp"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:32:40.791799+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rallybio posts Q1 net loss of $19.0M; cash $94.2M; on track for RLYB212 Phase 2 in 2H 2024

## Summary
- Net loss of $19.0M ($0.47 per share) vs $17.3M ($0.43 per share) in Q1 2023.
- Cash, cash equivalents, and marketable securities of $94.2M as of March 31, 2024; runway into mid-2026.
- Announced 45% workforce reduction in Feb 2024 to focus on RLYB212 and RLYB116.
- Collaboration with Johnson & Johnson (Momenta) for FNAIT; received $6.6M equity investment.
- Phase 2 trial of RLYB212 in pregnant women at risk for FNAIT on track for 2H 2024.

## SEC filing metadata
- accession: 0001739410-24-000053
- form_type: 8-K
- ticker: RLYB
- cik: 0001739410
- company_name: Rallybio Corp
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/0001739410-24-000053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/rlyb-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001739410-24-000053
- JSON: https://secwatch.observer/filing/0001739410-24-000053.json
- Plain text: https://secwatch.observer/filing/0001739410-24-000053.txt

## Key facts
- Earnings Releases
  Rallybio Corp reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Rallybio Corporation issued a press release announcing its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739410/000173941024000053/0001739410-24-000053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.